(Alliance News) - Angle PLC on Wednesday announced the publication of data confirming the good performance of its Parsortix system in isolating circulating tumour cells.
The liquid biopsy company based in Guildford, England said researchers at Western University and Lawson Health Research Institute in Ontario, Canada investigated the ability of the Parsortix system to harvest circulating tumour cells. The team used blood from healthy volunteers spiked with tumour cells from an epithelial breast cancer cell line and a mesenchymal prostate cancer cell line.
The researchers reported that the Parsortix system could harvest "significantly" more mesenchymal prostate circulating tumour cells than what is considered to be the leading antibody-based system, and comparable numbers of epithelial breast circulating tumour cells as well.
Shares in Angle were up 14% at 74.00 pence in London on Wednesday.
"Furthermore, the Parsortix system provides access to viable tumour cells for downstream analysis, making it an optimal platform for personalised medicine and for informing the development of targeted therapies. We look forward to harnessing Parsortix's unique capabilities as we continue to make strong progress with the establishment of approved clinical laboratories to support the use of the Parsortix system for pharma services and subsequent clinical deployment for clinical use," said Chief Executive Andrew Newland.
Angle submitted the Parsortix system to the US Food & Drug Administration in September, seeking the first ever FDA clearance for a system that harvests cancer cells from a blood draw for analysis. It believes the earliest prospect of clearance by the regulatory body is the first quarter of 2021.
By Zoe Wickens; zoewickens@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Angle (AGL)